A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2000 participants.
Also called NCT03344653
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 2,000 participants
- Sponsor
- Registry
-
NCT03344653
-
- Other papers using this trial's data
- Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Final 2-Year Results From Onyx ONE
- Polymer-based or Polymer-free Stents in Patients at High Bleeding Risk
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Australia, Austria, Belgium, Bulgaria, France, Hong Kong SAR China, Ireland, Italy, Latvia, Lithuania, Malaysia, Netherlands, New Zealand, Norway, Poland, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Thailand, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT03344653. Randomized; single masking; primary purpose treatment. Start 2017-11-02 (actual); primary completion 2018-09-27 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Randomized Controlled Trial With Resolute Onyx in One Month Dual Antiplatelet Therapy (DAPT) for High-Bleeding Risk Patients
- Acronym
- Onyx ONE
- Condition
- Coronary Artery Disease
- Intervention (Device)
- Medtronic Resolute Onyx Zotarolimus-Eluting Coronary Stent System
- Intervention (Device)
- Biosensors BioFreedom BA9 Drug Coated Coronary Stent
- Lead sponsor
- Medtronic Vascular
Record details
- Record id
cardio:ct-nct03344653- Content hash
9094cd0d8d30a9bb97d3850acd502e3ee8d1660cba275f6e0d1400826bcc86ee